Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
The expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Subscribe To Our Newsletter & Stay Updated
